FDAnews
www.fdanews.com/articles/202577-pfizer-buys-fungal-therapies-maker-amplyx

Pfizer Buys Fungal Therapies Maker Amplyx

May 3, 2021

Pfizer has acquired San Diego, Calif.-based Amplyx Pharmaceuticals, broadening its portfolio of potential therapies for treating drug-resistant fungal infections.

Under the deal, Pfizer gains access to Amplyx’s lead candidate, Fosmanogepix (APX001), a novel treatment for invasive fungal infections, as well as two early-stage candidates, an antiviral (MAU868) and another antifungal (APX2039).

Fosmanogepix is being evaluated in ongoing phase 2 trials in both intravenous and oral formulations for treatment of life-threatening fungal infections. Pfizer noted that no new antifungal therapies have been approved by the FDA in almost 20 years.

The financial terms of the purchase were not disclosed

View today's stories